Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ...

JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) after reducing its price objective from $950 to $800. Following poor IL-33 data in late May ...

J.P. Morgan sees mid-cap defense firms like Kratos rebounding in the second half of 2025 amid Pentagon-driven tailwinds.

Explore Regeneron Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for REGN. Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For ...

Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the 13 Biotech Stocks with Huge Upside Potential. Raymond James has started ...

New findings from the EVEREST Phase 4 trial presented at the 2025 EAACI Congress reveal that Dupixent (dupilumab) significantly outperformed Xolair (omalizumab) in treating adults with severe ...